VYNE Therapeutics Inc. (VYNE)

Name: VYNE Therapeutics Inc. (VYNE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: VYNE Therapeutics Inc. (VYNE)

Stock Card

$28.56

$3.11 (12.22%)

As on 27-Jul-2026 16:00EDT

Market cap

$19 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

VYNE Therapeutics (VYNE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 23.37 High: 28.56

52 Week Range

Low: 14.03 High: 79.75

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

37.91
EV/EBITDA

1.8
Debt to Equity

0
Book Value

$--
EPS

$-637.1
Face value

--
Shares outstanding

667,701

9 Years Aggregate

CFO

$-400.55 Mln

EBITDA

$-421.96 Mln

Net Profit

$-560.96 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
VYNE Therapeutics (VYNE)	4,823.3	4,307.4	4,327.9	1,856.2	97.8	-10.1	--
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Jul-2026 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
VYNE Therapeutics (VYNE)	-82.7	43.4	-13.7	-85.3	-83.9	-65.9	12.6
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
VYNE Therapeutics (VYNE)	28.6	19.1	1.0	-42.2	-1,671.9	-303.6	--	0.8
Amneal Pharmaceuticals Inc Class A (AMRX)	17.4	6,074.3	3,117.6	157.4	14.7	--	36.3	188.5
Axsome Therapeutics (AXSM)	206.7	10,826.1	776.6	-191.6	-17.6	-223.4	--	131.0
BridgeBio Pharma (BBIO)	74.8	14,630.7	691.8	-696.2	-89.1	--	--	123.7
Corcept Therapeutics (CORT)	111.6	12,065.9	830.8	54.9	3.2	8.1	248	17.3
Dr. Reddy's Laboratories - ADR	12.0	10,020.9	332,834.2	33,166.6	11.1	8.9	29.3	2.5
Elanco Animal Health (ELAN)	24.5	12,236.5	5,020.0	-199.0	1.6	-3	--	1.9
Ligand Pharmaceuticals (LGND)	285.6	5,693.6	290.5	197.2	82.5	19.9	29.8	5.9
Liquidia Technologies Inc (LQDA)	68.7	6,145.7	450.9	138.6	39.1	115.6	49	30.7
Twist Bioscience Corp (TWST)	124.7	8,210.6	431.8	-136.7	-30.8	-30.3	--	19.0

Shareholding Pattern

View Details

About VYNE Therapeutics (VYNE)

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small... molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey. Read more

CEO, President & Director

Mr. David T. Domzalski
CEO, President & Director

Mr. David T. Domzalski
Headquarters

Stewartsville, NJ
Website

https://vynetherapeutics.com

FAQs for VYNE Therapeutics (VYNE)

What is the current share price of VYNE Therapeutics Inc (VYNE) Today?

The share price of VYNE Therapeutics Inc (VYNE) is $28.56 (NASDAQ) as of 27-Jul-2026 16:00 EDT. VYNE Therapeutics Inc (VYNE) has given a return of 97.81% in the last 3 years.

What is the current PB & PE ratio of VYNE Therapeutics Inc (VYNE)?

Since, TTM earnings of VYNE Therapeutics Inc (VYNE) is negative, P/E ratio is not available.
The P/B ratio of VYNE Therapeutics Inc (VYNE) is 0.75 times as on 29-Jul-2026, a 90 discount to its peers’ median range of 7.69 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.02	0.02
2024	-0.07	0.05
2023	-0.25	0.08
2022	-0.02	0.01
2021	0.00	0.00

What is the 52 Week High and Low of VYNE Therapeutics Inc (VYNE)?

The 52-week high and low of VYNE Therapeutics Inc (VYNE) are Rs 79.75 and Rs 14.03 as of 06-Sep-2026.

What is the market cap of VYNE Therapeutics Inc (VYNE)?

VYNE Therapeutics Inc (VYNE) has a market capitalisation of $ 19 Mln as on 29-Jul-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in VYNE Therapeutics Inc (VYNE)?

Before investing in VYNE Therapeutics Inc (VYNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.